Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug:152:103008.
doi: 10.1016/j.critrevonc.2020.103008. Epub 2020 May 26.

A BRAF new world

Daniele Frisone  1 , Alex Friedlaender  2 , Umberto Malapelle  3 , Giuseppe Banna  4 , Alfredo Addeo  5
Affiliations
Review

A BRAF new world

Daniele Frisone et al. Crit Rev Oncol Hematol. 2020 Aug.

Abstract

BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlines that, rather than a single point mutation, BRAF genes present with a wide array of mutations, essentially in lung adenocarcinoma. Different BRAF mutations have divergent clinical and therapeutic implications, with a particular distinction between V600E and non-V600E mutations. The latter are at least as frequent in NSCLC as V600E, but lack any proven targeted therapy. In this paper, we briefly review the current literature and provide an update of scientific knowledge about different types of BRAF mutations in NSCLC.

Keywords: BRAF; NSCLC; Target therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Alfredo Addeo has has received compensation from Bristol-Myers Squibb, AstraZeneca, Merck Sharpe & Dohme, Takeda, Pfizer, Roche and Boehringer Ingelheim for participating on advisory boards. Alex Friedlaender has received compensation from Roche, Pfizer, Astellas and Bristol-Myers Squibb for service as a consultant. Daniele Frisone has no conflicts of interest. Giuseppe Banna reported receiving personal fees from Merck Sharp & Dohme, Boehringer Ingelheim, Janssen-Cilag, and Roche outside the submitted work. Umberto Malapelle Umberto Malapelle has received personal fees from Boehringer Ingelheim, Roche, MSD, Amgen, Merck, and Astrazeneca.

MeSH terms

Substances